X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

Pacific Biosciences Introduces New Chemistry With Longer Read Lengths to Detect Novel Features in DNA Sequence and Advance Genome Studies of Large Organisms

Thursday, October 3, 2013

MENLO PARK, Calif., Oct. 3, 2013 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), provider of the PacBio® RS II DNA Sequencing System, today announced significant new product enhancements to support researchers working on complex genome projects. The new P5 polymerase and C3 chemistry combination (P5-C3) extends the industry-leading sequence read lengths to an average of approximately 8,500 bases, with the longest reads exceeding 30,000 bases. A key feature of this performance enhancement is the inclusion of new photo-protected dyes, used to distinguish the four DNA bases using four colors of fluorescence. These photo-protected dyes shield the P5 polymerase from laser-induced damage, allowing the polymerase to
provide extremely long sequencing reads.

A complete genome sequence is an extremely valuable tool in many types of scientific research, yet most organisms do not have their complete genome assembled — including humans. Instead, complex genomes are partially completed with difficult repetitive sections and longer structural variants excluded from the assembly, resulting in highly fragmented, incomplete genomes. To sequence the complete genome of an organism, very long sequencing reads are required to span these regions, which can be critical in understanding gene function. The very long sequence reads provided by the PacBio RS II Single Molecule, Real-time (SMRT®) sequencing system provide researchers the opportunity to fill gaps or reduce the number of fragments in assemblies of moderate and large genomes.

“With the P5-C3 release, we saw another step change in the evolution of PacBio data,” said Dr. Paul Coupland, Research Scientist at the Wellcome Trust Sanger Institute, which served as a test site. “We obtained polymerase mean read lengths of greater than 8,500 bases, enabling us to span longer repeats, phase SNPs, and discover structural variants that were previously hidden. Our first data set was used for hybrid de novo assembly, and when combined with existing P4-C2 data the assembly was considerably improved.”

“Following our steady stream of system and chemistry improvements during 2013, including our v3 SMRT Cells, the PacBio RS II launch and the highly accurate polymerase P4, this release is our next generation chemistry upon which future developments and read length improvements will be built,” said Kevin Corcoran, Senior Vice President of Market Development for Pacific Biosciences. “Now 50% of the bases come from reads over 10,000 bases in length, nearly doubling the per-SMRT® Cell throughput. As our customers continue to sequence larger and more complex genomes, the long reads generated from P5-C3 chemistry make it an ideal choice for scaffolding and hybrid de novo assemblies.”

The latest release also includes 20,000-base size-selected library protocols optimized for use with the Sage Science BluePippin™ DNA size selection system, along with an upgraded version of SMRT Analysis (available at http://pacbiodevnet.com/), which introduces an update to the popular HGAP assembler. The new HGAP 2 assembler significantly decreases the time required to perform de novo genome assembly. These HGAP performance enhancements also extend the range of genome sizes that can be assembled. Additional software features include diploid-aware SNP detection as well as haplotype phasing of amplicons, which provides users the opportunity to utilize the platform for applications such as HLA analysis. The new reagents
are available in addition to the previously released P4-C2 chemistry, which is still recommended for PacBio-only de novo assembly, minor-variant detection, targeted sequencing, and cDNA applications.

Researchers attending the 2013 American Society of Human Genetics annual meeting in Boston can attend a workshop on October 24 from 12:30-2:00 p.m. to learn more about the PacBio RS II and hear from customers who are using the system.

More information about the PacBio RS II and the latest product enhancements is available at: www.pacb.com.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio® RS II DNA Sequencing System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, the company’s products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems. More information is available at www.pacb.com.

Forward Looking Statements

This press release contains forward-looking statements relating to the current or future performance of products and product enhancements.  You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company’s control and that could materially affect actual results. Factors that could materially affect actual results can be found in the Company’s filings with the Securities and Exchange Commission, including the most recently filed Quarterly Report on Form 10-Q, and include those listed under the caption “Risk Factors.” The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

CONTACT: For Pacific Biosciences:



         Media:

         Maurissa Messier

         For Pacific Biosciences

         760.539.7417

         maurissa@bioscribe.com



         Investors:

         Trevin Rard

         Pacific Biosciences

         650.521.8450

         ir@pacificbiosciences.com

Source: Pacific Biosciences of California, Inc.

News Provided by Acquire Media